DiaMedica Therapeutics Inc
Ownership
Ownership Structure
Who owns DiaMedica Therapeutics Inc (DMAC)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 46.9% of the shares are freely tradable; institutional investors hold 37.9%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Cooperman Leon G | 6.40 | 3,450,000 | +70.8 | 06/30/2026 |
| BlackRock Inc | 3.44 | 1,856,187 | -2.4 | 03/31/2026 |
| PARAGON Assoc & PARAGON Assoc II JV | 1.62 | 875,000 | +0.0 | 03/31/2026 |
| Millennium Management LLC | 1.57 | 845,309 | -9.6 | 06/30/2026 |
| Geode Capital Management, LLC | 1.45 | 780,516 | +2.1 | 03/31/2026 |
| State Street Corp | 1.19 | 644,211 | +2.6 | 03/31/2026 |
| First Manhattan Co. LLC | 0.84 | 455,000 | +12.3 | 03/31/2026 |
| Bleichroeder LP | 0.71 | 382,317 | +0.0 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| iShares Russell 2000 ETF | 1.70 | 919,292 | -0.6 | 08/31/2026 |
| Fidelity Small Cap Index | 0.74 | 398,550 | +16.8 | 06/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Pauls Dietrich John | President & CEO | 128,791 | 888,658 $ | Aug 10, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 10, 2026 | Pauls Dietrich John | President & CEO | Other | 60,200 | 0.00 | – |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.